Patricia Inácio, PhD, science writer —

Targeting a membrane protein called TMEM16F may help reduce the spread of toxic clumps, or aggregates, of alpha-synuclein — a hallmark of Parkinson’s disease — across the brain, according to a new study by a team in Israel. The scientists found that a genetic variant of the TMEM16F gene…

The planned Phase 2 SUNRISE-PD clinical trial of oral bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s disease patients is scheduled to begin in early 2025. BioVie, the therapy’s developer, has secured over $15 million to cover complete costs of the trial, and top-line findings are…

Zimmer Biomet announced that it has acquired select exclusive rights to distribute NeuroOne’s OneRF Ablation System, a brain electrode-guided tool for use in neurological brain surgeries, including those for Parkinson’s disease. “As the world’s first FDA [U.S. Food and Drug Administration] cleared system for both diagnostic…

A researcher at the University of Rhode Island has received nearly $500,000 in federal funding to investigate the neuronal changes underlying visual hallucinations — seeing something that is not real — in people with Parkinson’s disease. The funding, from the National Science Foundation, was granted to Yalda Shahriari, PhD,…

Adding Cerevance’s investigational oral therapy solengepras (CVN424) to standard Parkinson’s disease treatment significantly decreased off time, when symptoms return or worsen, according to the data from a completed Phase 2 trial. The trial met its main efficacy goal, with a reduction in average off time at the…

Amprion said it has raised the initial $6 million of a $15 million financing deal that will help develop and commercialize SAAmplify, its diagnostic test for Parkinson’s disease and other neurodegenerative conditions linked to the formation of toxic clumps by the protein alpha-synuclein. The test, SAAmplify, was…

The first patient with early Parkinson’s disease has been dosed in Ventyx Biosciences‘ Phase 2a clinical trial of Parkinson’s therapy VTX3232, an oral medication designed to reduce inflammation by blocking the activity of the NLRP3 protein. The trial is still recruiting patients at its single site in…

Regeneron has joined the data syndication program for Koneksa‘s LEARNS study that’s assessing the potential of digital biomarkers for measuring the progression of Parkinson’s disease. The program enables Regeneron to gain immediate and continuous access to data and results as the trial progresses, which may accelerate the…

Understanding and identifying epigenetic changes — those that affect gene activity without altering a gene’s DNA sequence — in blood samples from people with Parkinson’s disease and other neurological conditions may help assess the risk of dementia, two independent studies suggest. In one study, changes in DNA methylation, one…

A Phase 1 trial of ALX-001, an investigational therapy for neurodegenerative conditions, has dosed the first patient with Parkinson’s disease. The clinical trial (NCT06309147) is assessing the safety of Allyx Therapeutics‘ ALX-001 versus a placebo when given twice a day at either 50 mg or 100 mg for…